This Belgian Startup Just Raised $6.5M to Make Cancer Drugs Work Faster

Jan de Vries · 2026-10-09

What if the biggest bottleneck in cancer treatment isn't the science itself, but the tools used to test it? That's the question a new Belgian startup is betting millions on. SpectaCell, a Ghent-based life sciences company, just launched with €6 million — roughly $6.5 million — in seed funding. The company spun out of imec, VIB, and Ghent University, and it's building a next-generation cell analysis platform aimed at speeding up immunotherapy development. ### Who's Behind the Money The round was led by imec.xpand, with participation from PMV's Flanders Future Tech Fund, InnovationQuarter Capital, Qbic, and VIB. That's a serious lineup of backers for a company that's barely out of the gate. Benoit Devogelaere, Partner at imec.xpand, didn't hold back: *"SpectaCell brings together disruptive semiconductor technology, an experienced team and a major commercial opportunity in drug development and manufacturing."* He added that they see the potential to "set a new industry standard and build a globally competitive life-sciences business." ### The Problem They're Solving Here's the thing about immunotherapy — it's one of the most promising frontiers in cancer treatment. It works by helping your immune system recognize and attack cancer cells. But predicting which treatments will actually work in patients? That's still painfully hard. Most existing tests give you indirect signals or averages across a sample. And when you're dealing with individual cells, averages can hide critical differences. As SpectaCell puts it, important variations between cells "can disappear in those averages." That means developers are often flying blind early in the process. Slow, fragmented testing creates gaps in understanding and delays decisions — while patients wait. ### How SpectaCell's Tech Works SpectaCell combines chip-based imaging with data analysis to track large numbers of individual cells directly, at high resolution, over time. No fluorescent labels required — those can interfere with how cells behave naturally. The company is developing a cartridge-based instrument designed to deliver insights in hours rather than days. It's targeting pharmaceutical and biotech companies worldwide, from early research through to routine manufacturing quality checks. - Compare drug candidates more effectively - Improve production processes - Assess whether each batch meets performance standards ### Why This Matters for the U.S. Market American biopharma companies are pouring billions into cell therapies and T-cell engagers. But the tools for evaluating these treatments haven't kept pace. A platform that delivers faster, more granular data could shave months — maybe years — off development timelines. Tony Montoye, CEO and co-founder, summed it up: *"Breakthrough medicines need breakthrough tools. Researchers need to know much earlier which candidates deserve further investment and why."* SpectaCell was founded in 2026 by Mathieu Rabaey, Veronique De Vroey, Jan Van de Velde, and Tony Montoye. The company plans to use the fresh capital to fund further development and commercialization with pharma partners. The bottom line? Better tools mean better decisions. And better decisions mean better medicines, sooner. That's something we can all get behind.